Performance of the flow cytometry-based in vitro micronucleus assay in a validation study

2016 ◽  
Vol 258 ◽  
pp. S316
Author(s):  
D.J. Smart ◽  
F. Helbling ◽  
P. Blandine ◽  
M. Damian ◽  
V. Patrick
Author(s):  
John W. Wills ◽  
Jatin R. Verma ◽  
Benjamin J. Rees ◽  
Danielle S. G. Harte ◽  
Qiellor Haxhiraj ◽  
...  

AbstractThe in vitro micronucleus assay is a globally significant method for DNA damage quantification used for regulatory compound safety testing in addition to inter-individual monitoring of environmental, lifestyle and occupational factors. However, it relies on time-consuming and user-subjective manual scoring. Here we show that imaging flow cytometry and deep learning image classification represents a capable platform for automated, inter-laboratory operation. Images were captured for the cytokinesis-block micronucleus (CBMN) assay across three laboratories using methyl methanesulphonate (1.25–5.0 μg/mL) and/or carbendazim (0.8–1.6 μg/mL) exposures to TK6 cells. Human-scored image sets were assembled and used to train and test the classification abilities of the “DeepFlow” neural network in both intra- and inter-laboratory contexts. Harnessing image diversity across laboratories yielded a network able to score unseen data from an entirely new laboratory without any user configuration. Image classification accuracies of 98%, 95%, 82% and 85% were achieved for ‘mononucleates’, ‘binucleates’, ‘mononucleates with MN’ and ‘binucleates with MN’, respectively. Successful classifications of ‘trinucleates’ (90%) and ‘tetranucleates’ (88%) in addition to ‘other or unscorable’ phenotypes (96%) were also achieved. Attempts to classify extremely rare, tri- and tetranucleated cells with micronuclei into their own categories were less successful (≤ 57%). Benchmark dose analyses of human or automatically scored micronucleus frequency data yielded quantitation of the same equipotent concentration regardless of scoring method. We conclude that this automated approach offers significant potential to broaden the practical utility of the CBMN method across industry, research and clinical domains. We share our strategy using openly-accessible frameworks.


2010 ◽  
Vol 52 (5) ◽  
pp. 363-372 ◽  
Author(s):  
Magdalena Lukamowicz ◽  
Katherine Woodward ◽  
Micheline Kirsch-Volders ◽  
Willi Suter ◽  
Azeddine Elhajouji

2012 ◽  
Vol 53 (4) ◽  
pp. 260-270 ◽  
Author(s):  
Magdalena Lukamowicz-Rajska ◽  
Micheline Kirsch-Volders ◽  
Willi Suter ◽  
Hansjoerg Martus ◽  
Azeddine Elhajouji

2020 ◽  
Vol 7 ◽  
pp. 1010-1019 ◽  
Author(s):  
David Thorne ◽  
James Whitwell ◽  
Julie Clements ◽  
Paul Walker ◽  
Damien Breheny ◽  
...  

2011 ◽  
Vol 205 ◽  
pp. S109
Author(s):  
A. Rogue ◽  
R. Josse ◽  
E. Lorge ◽  
A. Guillouzo

Sign in / Sign up

Export Citation Format

Share Document